Retina Institute Japan K.K., which is employing Nobel Prize-winning stem-cell technology to treat eye diseases, plans to sell a stake in itself to a group of Japanese companies next month ahead of a possible initial public offering in five years.
http://washpost.bloomberg.com/Story?docId=1376-MLCCL06KLVRL01-56IC68QRFJ16CLJ2JBKAED6Q6J
http://washpost.bloomberg.com/Story?docId=1376-MLCCL06KLVRL01-56IC68QRFJ16CLJ2JBKAED6Q6J
No comments:
Post a Comment